###### Article summary

Article focus
=============

-   Transcatheter aortic valves can be indicated for patients unfit for surgery or as an alternative to surgical valve replacement.

-   No difference in mortality at 2 years was found in one randomised trial comparing transcatheter valve versus surgical replacement.

-   No systematic review has studied survival after 2 years and limited information is available on between-study heterogeneity.

Key messages
============

-   In our meta-analysis of 14 studies, pooled survival rates at 2 and 3 years were 69.0% and 61.4%, respectively.

-   Survival rates up to 2 years were similar to those reported in the randomised trial.

-   Immediate and intermediate death rates were worse than those reported in a recent meta-analysis of 48 studies examining patients aged \>80 years who underwent conventional isolated aortic valve replacement.

Strengths and limitations of this study
=======================================

-   Our study conveys original information beyond 2 years in a quite large series of studies.

-   Although our analysis examined a total of about 3500 patients, only a minority of these were actually followed up after 2 years.

Introduction {#s1}
============

Although the results at 2 years of the randomised PARTNER trial have shown similar death rates between transcatheter aortic valve implant (TAVI) and conventional aortic valve replacement (AVR),[@R1] extending this comparison on the basis of other studies can be worthwhile.

With regard to surgery, a recent meta-analysis has examined survival in patients aged ≥80 years undergoing conventional isolated AVR.[@R2] From the analysis of 48 studies summarising the experience of three decades, Vasques *et al*[@R2] reported a pooled death rate at 2 years of 16.4% (95% CI 14.4% to 18.4%), which is clearly a more favourable outcome than has commonly been thought so far.

The experience with TAVI is much more recent. One meta-analysis of 16 studies has systematically determined the rates of major outcomes up to 1 year,[@R3] but limited information is available on late results.[@R3] [@R4] The presence of a learning curve has consistently affected the results produced by this device,[@R5] therefore, only the most recent studies are likely to reflect the outcomes expected with this technique.

For these reasons, we undertook the present meta-analysis of available studies to summarise the current data on the intermediate outcome after TAVI.

Methods {#s2}
=======

Study design {#s2a}
------------

Our study was designed to examine mortality at 2 years or more after TAVI, and so we excluded those studies based on follow-up less than 2 years. Furthermore, we limited our literature search to the period from January 2010 to June 2012 in order to restrict the analysis to the most recent studies, which are likely not affected by a learning curve. We retrieved many types of clinical studies (randomised trials, observational studies, single-centre study). All kind of prostheses so far implanted in humans were included in the present analysis. The keywords used for our search were: '*aortic valve' AND (percutaneous OR transcatheter)*, combined with the limitations '*only item with abstract*' and '*publication date from 2010 to 2012*'. Statistical analysis was carried out in the form of a proportion meta-analysis that generated study-specific rates of 1-year to 3-year mortality with their respective 95% CIs. Besides the data on survival at 2 years or more, additional information on baseline patient\'s and operative characteristics was extracted.

Management of survival information from Kaplan-Meier curves {#s2b}
-----------------------------------------------------------

Our study included a simplified analysis (in which the absolute event rates from the studies were determined on the basis of an approximate method[@R6]) and a more complex analysis (in which each Kaplan-Meier curve of the various studies was subjected to a complete reconstruction of the number of events along with their respective timings according to the recommendations of Tierney *et al*[@R7]). Since the simplified analysis gave the same results as those obtained from the more complex one, only the former is presented herein.

In the simplified analysis, the death rates at 2 years (death rates from any cause) were handled as follows. In those studies where all patients had been followed up until at least 2 years (with the obvious exception of deaths before 2 years), the percent death rate at 2 years was simply the ratio between the number of deaths observed within this time interval and the total number of enrolled patients multiplied by 100. In the remaining cases (ie, in studies with censored patients), the death rate at 2 years was directly obtained from the Kaplan-Meier curve presented in the original study.

The study-specific input information for a proportion meta-analysis is represented by the ratio of number of deaths and number of patients entering the interval, and moreover, the denominator of this ratio acts as a study-specific statistical weight for the meta-analysis. In studies including censoring, to estimate numerators and denominators at specific time-points consistently with the purposes of our meta-analysis, we used the method of Stewart and Parmar.[@R6] Accordingly, assuming that the number of patients still at risk at the time-point concerned (eg, at 2 years) is known (eg, N~AR~ ~−~ ~2\ years~), this denominator (adjusted for the number of patient-years accumulated) is calculated from the following equation:

where RATE~KM−2 years~ is the mortality Kaplan-Meier rate (expressed from 0 to 1).

Likewise, adjusted numerators at the time-point concerned were calculated as:

Finally, the adjusted study-specific crude event rate was determined as: (adjusted numerator)/(adjusted denominator).

According to these equations, if the number of enrolled patients at time zero is N~AR-time\ 0~ and mortality at the time point concerned differs from 0, the 'adjusted denominator' is by definition less than N~AR-time\ 0~. For obvious mathematical reasons, one exception takes place when no patients have been lost to follow-up over the initial 2 years (or, in other words, when all living patients have been followed up until at least 2 years) because in these cases the 'adjusted denominator' is equal to N~AR-time\ 0~.

This method of downward readjustment of the denominator has the purpose to reduce (from the number of enrolled patients at time zero, or N~AR-time\ 0~, to 'adjusted denominator') the statistical weight of the studies in which some of the patients initially at risk have not been followed up until the time-point concerned.

In our analyses at 1 and 3 years, similar equations were employed. In all of these three analyses, we planned to contact the investigators for cases where the raw data needed for our survival analysis could not be extracted as indicated above.

In the more complex analysis not presented in this paper, the same readjustment of the study-specific statistical weights was performed using the method described by Tierney *et al.*[@R7]

Meta-analysis {#s2c}
-------------

The death rates at 2 years for individual studies were then analysed according to a proportion meta-analysis using the random effect model. The pooling methods were the same as those reported in a previous study[@R2] and in numerous other studies[@R8] as well. Our meta-analytic results included: (1) the 95% CI for individual study-specific rates; (2) the meta-analytical pooled rate at 1, 2 and 3 years with 95% CI; (3) standard indexes assessing between-study heterogeneity including I^2^ and Cochran\'s Q. Our meta-analysis was rerun under different conditions and particularly after excluding specific studies that were thought to be responsible for the large heterogeneity found in our primary analysis.

Meta-regression, in which we tested whether death rates were affected by specific covariates, was carried out as previously described.[@R2] Finally, because of the one-arm and observational nature of the included studies, our analysis did not include any adjustment aimed at evaluating publication bias.

Results {#s3}
=======

Our literature search on PubMed yielded 963 eligible articles, which were scrutinised by two co-authors (AM and ST). [Figure 1](#BMJOPEN2012001770F1){ref-type="fig"} illustrates the PRISMA diagram of our search. A total of 14 studies[@R1] [@R9; @R10; @R11; @R12; @R13; @R14; @R15; @R16; @R17; @R18; @R19; @R20; @R21] reporting on 3496 patients met our inclusion criteria and were included in our analysis. [Tables 1](#BMJOPEN2012001770TB1){ref-type="table"} and [2](#BMJOPEN2012001770TB2){ref-type="table"} summarise the main characteristics of these studies.

###### 

Characteristics of studies and baseline variables of patients who underwent transcatheter aortic valve implantation included in this analysis

  First author            Year   Type of study   Type of prosthesis        Study period       Number of patients   Age         Mean STS score   Mean Logistic EuroSCORE   Coronary artery disease (%)   Prior CABG/cardiac surgery (%)   Prior PCI (%)   Peripheral vascular disease (%)   Cerebro- vascular disease (%)   Pulmonary disease (%)   LVEF (%)
  ----------------------- ------ --------------- ------------------------- ------------------ -------------------- ----------- ---------------- ------------------------- ----------------------------- -------------------------------- --------------- --------------------------------- ------------------------------- ----------------------- -----------
  Abdel-Wahab[@R9]        2012   R, SC           CoreValve                 09.2007--03.2011   125                  81.0±6.4    --               24.3±13.8                 72.8                          19.2                             30.4            16.8                              10.4                            --                      47.7±14.5
  Attias[@R10]            2010   P, SC           SAPIEN /CoreValve         10.2006--06.2009   83                   81±9        15±8             26±14                     50.6                          21.7                             19.3            27.7                              --                              32.5                    52±15
  Bleiziffer[@R11]        2012   P, SC           SAPIEN /CoreValve         06.2007--03.2009   227                  81±7        7±5              21±14                     52.0                          18.5                             --              26.9                              18.1                            22.9                    --
  Buellesfeld[@R12]       2011   P, MC           CoreValve                 2006--2009         126                  81.9±6.4    --               23.4±13.8                 65.9                          26.2                             23.8            19.1                              22.2                            23.0                    --
  D\'Onofrio[@R13]        2011   P, MC           SAPIEN                    04.2008--09.2010   504                  81.2±6.5    11.0±4.0         26.3±13.8                 50.4                          16.5                             22.0            45.4                              --                              34.3                    52.4±13.6
  Gasparetto[@R14]        2012   P, SC           SAPIEN /CoreValve         06.2007--04.2011   191                  80.5±56.0   --               21.4±13.4                 59.2                          15.2                             14.1            --                                31.9                            27.8                    54.3±12.9
  Kalavrouziotis [@R15]   2011   P, SC           SAPIEN                    04.2007--07.2010   35                   79.2±9.4    7.5±3.6          18.8±14.1                 60.0                          31.4                             34.3            --                                28.6                            17.1                    59±13
  Kodali[@R1]             2012   RCT             SAPIEN                    05.2007--08.2009   348                  83.6±6.8    11.8±3.3         29.3±16.5                 74.7                          42.5                             33.3            42.8                              27.6                            43.7                    52.5±13.5
  Makkar[@R16]            2012   RCT             SAPIEN                    05.2007--03.2009   179                  83.1±8.6    11.2±5.8         26.4±16.2                 67.6                          32.4                             26.3            30.2                              26.8                            41.3                    53.9±13.1
  Moat[@R17]              2011   P, SC           SAPIEN /CoreValve         01.2007--12.2009   870                  81.9±7.1    --               --                        47.1                          --                               --              29.0                              --                              28.7                    --
  Ussia[@R18]             2012   P, MC           CoreValve                 06.2007--08.2008   181                  80.9±6.1    11.4±9.9         24.0±13.5                 53.0                          18.8                             28.2            14.9                              --                              18.8                    --
  Walther[@R19]           2012   P, SC           SAPIEN                    02.2006--01.2010   299                  82.1±6.4    12.0±7.7         31±15.8                   --                            28.1                             --              47.2                              18.7                            43.1                    55±14
  Wenaweser[@R20]         2011   P, SC           SAPIEN /CoreValve         07.2007--09.2010   257                  82.1±6.2    6.4±5.0          24.7±24.9                 65.0                          21.0                             22.6            24.9                              9.0                             --                      51±14
  Ye[@R21]                2010   P, SC           Cribier--Edwards/SAPIEN   10.2005--02.2009   71                   80.0±8.1    12.1±7.7         34.5±20.4                 74.7                          43.7                             43.7            85.9                              31.0                            28.2                    --

CABG, coronary artery bypass grafting; EuroSCORE, European System for Cardiac Operative Risk Evaluation; LVEF, left ventricular ejection fraction; MC, multicenter; P, prospective; PCI, percutaneous coronary intervention; R, retrospective; RCT, randomised controlled trial; SC, single center; STS, Society of Thoracic Surgeons.

###### 

Operative data and immediate outcome in patients who underwent transcatheter aortic valve implantation included in this analysis

  First author           Year   Transapical approach (%)   Associated PCI (%)   Implantation success (%)   In-hospital/30-days stroke (%)   30-days mortality (%)
  ---------------------- ------ -------------------------- -------------------- -------------------------- -------------------------------- -----------------------
  Abdel-Wahab [@R9]      2012   0                          44.0                 100                        6.0                              4.0
  Attias[@R10]           2010   100                        0                    94.0                       4.8                              7.2
  Bleiziffer[@R11]       2012   23.8                       --                   --                         2.6                              11.5
  Buellesfeld[@R12]      2011   0                          --                   83.3                       9.6                              15.1
  D\'Onofrio [@R13]      2011   100                        --                   99.2                       3.0                              8.3
  Gasparetto[@R14]       2012   30.4                       20.4                 95.3                       1.6                              4.2
  Kalavrouziotis[@R15]   2011   68.6                       --                   97.1                       0                                2.9
  Kodali[@R1]            2012   30.0                       0                    94.3                       4.6                              3.5
  Makkar[@R16]           2012   0                          0                    96.7                       6.7                              5.0
  Moat[@R17]             2011   26.4                       6.3                  97.3                       4.1                              7.1
  Ussia[@R18]            2012   0                          --                   91.7                       2.8                              11.0
  Walther[@R19]          2012   100                        --                   --                         0.7                              8.7
  Wenaweser[@R20]        2011   21.4                       23.4                 99.6                       3.9                              6.6
  Ye[@R21]               2010   100                        --                   100                        1.4                              16.9

PCI, Percutaneous coronary intervention.

![PRISMA diagram of our literature search. Other sources for identification of further articles included EMBASE and Scopus. The lack of survival information at 2 years was the only reason for the final exclusion of 12 studies. Last search was run on 1 July 2012.](bmjopen2012001770f01){#BMJOPEN2012001770F1}

The raw data extracted from the trials were adequate for our analysis, and so we did not have to contact any investigators. The pooled immediate postoperative death rate was 7.8% (95% CI 6.2% to 9.8%, I^2^=40.8%; Cochran\'s Q=97.7 with 93 df, p\<0.0001) and stroke rate was 3.8% (95% CI 2.8% to 5.0%, I^2^=34.3%; Cochran\'s Q=96.5 with 93 df, p\<0.0001).

Pooled death rates at 1, 2 and 3 years were 23.2%, 31.0% and 38.6%, respectively. Survival data are reported in [figures 2](#BMJOPEN2012001770F2){ref-type="fig"} and [3](#BMJOPEN2012001770F3){ref-type="fig"}. Only six studies reported data on 3-year mortality, and therefore we restricted further analysis at results at 2 years.

![Survival after transcatheter aortic valve implant: the solid line (with circles) indicates the pooled results of our analysis while the dashed lines represent 95% CIs.](bmjopen2012001770f02){#BMJOPEN2012001770F2}

![Study-specific death rates and pooled meta-analytic rates at 1 (upper panel), 2 (intermediate panel) and 3 years (lower panel) after transcatheter aortic valve implant; for each study, N indicates the adjusted denominator at the time-point concerned; CIs are at 95%.](bmjopen2012001770f03){#BMJOPEN2012001770F3}

At 2 years, indexes of heterogeneity consistently were at levels of statistical significance (I^2^=52.1%; Cochran\'s Q=27.2 with 13 df, p=0.012). Furthermore, 95% CI of the death rate ranged from 25.7% to 36.6% indicating considerable variability in this outcome end-point. Reasons that can explain this heterogeneity likely reside in the criteria for patient selection. [Figure 3](#BMJOPEN2012001770F3){ref-type="fig"} clearly shows that patients classified as inoperable in the studies by Makkar *et al*[@R16] and Kodali *et al*[@R1] showed an increased mortality at 2 years. However, the between-study heterogeneity remained significant even after exclusion of these two trials (data of this sensitivity analysis not shown).

Sensitivity analysis for logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) showed that at 2 years, studies reporting on patients with a logistic EuroSCORE \<25% had a pooled death rate of 31.4% (95% CI 26.4% to 36.5%), whereas it was 32.5% (95% CI 24.7% to 41.3%) among patients with a logistic EuroSCORE\>25%.

Similarly, sensitivity analysis for Society of Thoracic Surgeons (STS) score showed that at 2 years studies reporting on patients with a STS score \<10% had a pooled death rate of 33.8% (95% CI 28.6% to 39.4%), whereas it was 32.0% (95% CI 26.1% to 38.6%), among patients with a STS score \>10%. These findings were confirmed at meta-regression (p=0.802).

Interestingly, data from four studies[@R9] [@R14] [@R17] [@R20] reporting on concomitant percutaneous coronary intervention (PCI) showed a somewhat lower death rate at 2 years (25.8%, 95% CI 22.0% to 30.1%, I^2^=0%; Cochran\'s Q=59.9 with 75 df, p\<0.0001). These improved results were consistent with somewhat lower mortality at 30 days (6.3%, 95% CI 5.0% to 8.0%, I^2^=12.0%; Cochran\'s Q=77.6 with 75 df, p\<0.0001) and 1 year (17.8%, 95% CI 13.5% to 23.0%, I^2^=39.3%; Cochran\'s Q=89.5 with 75 df, p\<0.0001). Scarce data on the extent of coronary artery disease and revascularisation policy prevented further comparative analysis. However, assuming that no concomitant PCI was performed in the other studies, meta-regression showed that a policy of coronary revascularisation was associated with significantly better 2-year survival (coefficient −0.004, p=0.024).

Finally, transapical approach did not affect 2-year survival according to meta-regression (p=0.736).

Discussion {#s4}
==========

Our article raises a number of issues particularly if our findings are interpreted in the framework of other recent reports. First, the recent publication of the survival results from the SOURCE registry[@R22] allow us to compare the death rates at 1 year between the population included in our meta-analysis (3496 patients; 1-year mortality=23.2%) and the large patient series included in this registry (3195 patients; 1-year mortality=24.0%). While it should be stressed that the population enrolled in the SOURCE registry could not be included in our analysis due to the lack of survival data after 1 year, these nearly identical results at 1 year suggest a good representativeness of the patients of our meta-analysis.

Since TAVI still is a rather novel procedure, data on the longer term outcome can be important and the 2-year results of the PARTNER trial (33.9% mortality) are particularly relevant from this point of view, also because they agree with those found in our meta-analysis (31.0% mortality at 2 years). The purpose of our analysis to study outcomes from other studies is worthwhile not only because information up to 3 years was estimated but also because information was obtained about the between-study variability of these outcomes.

Although a difference in 2-year mortality favouring AVR over TAVI could be suggested by indirectly comparing the present findings (31.0% with 95% CI of 25.7% to 36.6%) with pooled data of conventional surgery in octogenarians (16.4%, 95% CI 4.4% to 18.4%),[@R2] the PARTNER trial showed no such a difference. While the reasons underlying this discrepancy cannot be easily identified, one explanation can be that a variety of known and possibly unknown factors still tend to generate less reliable results with TAVI than those, more reproducible, reported with conventional surgery. This hypothesis is in keeping with the significant heterogeneity found across the TAVI studies included in our meta-analysis.

In patients fit for surgery, mortality risk after isolated AVR has significantly decreased during the last decade presumably because of improvements in anaesthesiological and peri-operative care as well as the introduction of mini-sternotomy AVR.[@R23] This may explain why patients aged \>80 years undergoing AVR nowadays show unexpectedly good survival rates.[@R2] In light of this evidence, TAVI can be seen as a valid alternative in the very elderly only if the operative risk is prohibitive. Indeed, when operative risk of very elderly patients is not prohibitive their immediate and late survival after AVR are excellent.[@R2]

The impact of coronary artery disease and the benefits and risks associated with its concomitant treatment cannot be addressed in this meta-analysis. Even if coronary artery disease requiring revascularisation was an exclusion criteria in a few studies, the prevalence of coronary artery disease may have a significant impact on the early and late outcome of these patients[@R18] as suggested by better immediate and intermediate survival rates reported in a few series.[@R9] [@R14] [@R17] [@R20] However, at this stage, scrutiny of the value of hybrid approach is not possible because of lack of specific data on the prevalence of coronary artery disease requiring revascularisation and timing of PCI.

A major limitation of our study is the fact that in studies with a follow-up beyond 2 years, the patients who reached this follow-up length were only 10% of the population initially enrolled. Another weakness of this analysis is the lack of information at individual patient level which prevented us from assessing the prognostic value of important clinical covariates and concomitant PCI.

The debate on the role that TAVI can have in the present therapeutic scenario is very lively, and conflicting opinions have recently been published.[@R24] [@R25] At the same time, although further studies on outcomes have been made available,[@R3] [@R26] no additional information on the results beyond 2 years has been published.

In conclusion, despite the high level of heterogeneity, our pooled analysis of available survival data supports the effectiveness of TAVI at 2 or 3 years. TAVI can offer rather durable intermediate results and can therefore be considered a valid treatment in high-risk patients. However, lack of data on structural durability at this stage prevents its use in patients with low operative risk and long expectancy of life.
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